StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Canaccord Reiterates Buy Rating on Intellia Therapeutics (NTLA)
June 16, 2026 6:37 AM
Canaccord analyst Whitney Ijem reiterated a Buy rating and $49.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst commented: "Over ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
